nation beverag corp hold result miss ebitda gross margin ep revenu in-line
inc buy pt increas headwind manag express
measur optim boston meet maintain buy pt analyst stephen anderson full summari
revenu growth maintain buy pt peer acquisit analyst tate sullivan cfa full summari
vistagen inc vtgn buy pt catalyst ahead elev data vistagen also
analyst jason mccarthi ph full summari
corpor event call maxim salesperson inform
zosano pharma corpor zsan cover vendetti ndr nyc ceo john walker cfo greg kitchen
trovagen inc trov cover mccarthi ndr nyc ceo tom adam cso mark erland tue jul
annual silicon valley bu tour zs host chokshi tue jul
increas headwind manag express
measur optim boston meet maintain buy
reiter buy rate price target cracker barrel old
countri store follow investor meet host
manag boston tuesday june
anticip anoth year compar sale growth restaur
busi ttm sale though model mute comp
growth retail busi ttm sale
manag expect increment food labor cost headwind
believ consist comp growth cost save contribut low-teen
percentag ep growth period
manag express confid revis capit alloc strategi
believ uptick unit develop like
ep estim unchang vs street juli
vs street vs street
street mean avail
june host investor meet cfo golder boston
view prevail tone one measur optim face tepid
anticip anoth year compar sale growth restaur
busi ttm sale though model mute comp
growth retail busi ttm sale manag offer
cautious optimist state consum particularli light y/i
declin gasolin price import busi
deriv long-dist travel expect restaurant-level catalyst
continu growth off-premis busi well follow-up line
extens recent success launch signatur chicken although
retail busi remain challeng particularli internet-bas competit
believ cbrl best opportun reviv retail sale food-and-
manag expect increment food labor cost headwind
believ consist comp growth cost save contribut low-teen
percentag ep growth period specif expect
import increment headwind like come commod cost
though light recent moder key commod cost estim
pace food cost inflat like rang slightli
current pace inflat
still model share price upsid share trade
ep estim ep estim compar
peer multipl publicli trade full-servic dine chain expect
invest year return low-teen ep pace
new price target correspond roughli unchang
ep estim also correspond forward ev/ebitda ratio
line cbrl five-year averag multipl peer
averag moreov cbrl combin dividend yield includ special
dividend declar past five year expect
click full note
revenu growth maintain buy pt peer
right end current quarter sector acquisit earlier
week maintain forecast acceler y/i rental revenu
growth due rent larger natur ga compress equip
rental revenu increas y/i forecast y/i rental
revenu growth
comparison total revenu may increas lower amount rental
revenu due sporad revenu million sale backlog
anticip total y/i revenu growth
forecast slightli lower rate annual ebitda growth account lower
margin sale higher cost start rental contract still
anticip y/i ebitda growth increas
expect share anticip acceler y/i growth revenu
ebitda result maintain buy rate
separ far week share natur ga compress
equip competitor rate share increas
announc acquisit
recommend buy share invest sustain growth
natur ga demand base part lower leverag publicli trade
peer believ offer investor sustain less volatil option
invest grow natur ga demand net cash compar peer group
averag net debt billion ahead acceler revenu
growth peer group alreadi increas revenu
sustain demand natur ga help rent compressor
believ demand increas equip natur ga
pipelin natur ga power plant liquefi natur ga export petrochem
plant export natur ga start increas base new
liquefi natur ga facil also natur ga power plant continu gener
electr coal-fir power plant close custom
move natur ga well pipelin expect rent larger
compressor push natur ga back well increas oil product believ
ga lift process help maintain current level oil product
announc natur ga compress equip acquisit earlier
week million bought elit compress servic privat pre-
synergi valu ebitda comparison current ev/ebitda multipl
expect fund million transact sell idl horsepow
million million cash share deal present
indic sustain natur ga product growth creat stabl price
natur ga compressor wherea new compressor help custom
increas oil product ga lift process indic elit larg
maintain buy rate price target price target base
unchang ebitda forecast million current ev/ebitda multipl
base ebitda forecast line peer group averag use
higher target multipl valu share base expect acceler
revenu growth rent larger compressor
click full note
result miss ebitda gross margin
yesterday market close report apr ebitda gross
margin ep estim revenu in-line
believ lacroix deceler growth weigh financi
reduc forecast introduc estim
bottom line remain sidelin even report revenu in-line
consensu ebitda gross margin ep estim
believ portfolio still contain mani stagnant brand reli heavili
lacroix drive overal growth lacroix growth continu deceler expect
drag overal financi perform higher cost-of-sal per case primarili
relat aluminum freight cost increas weaken gross margin
past year lastli remain skeptic compani corpor govern
disclosur practic aforement reason maintain hold rate
result summari yesterday market close report
revenu y/i estim in-line
consensu gross margin y/i
estim consensu margin contract due primarili
higher manufactur aluminum cost ebitda y/i
estim consensu ep
y/i well estim consensu
full-year metric apr case volum power segment
includ lacroix among brand grew y/i carbon soft
drink segment declin calcul power made total
sale volum believ remain volum carbon soft
drink csd flat-to-down last five year gross margin
contract higher cost-of-sal per case rose
primarili due higher aluminum manufactur cost ship handl cost
y/i increas percentag revenu
consist higher aluminum freight cost observ
across industri market cost grew increas revenu
oper expens grew remain revenu
reduc estim due lower-than expect revenu
expect continu pressur lacroix reduc apr
revenu estim moreov lower ebitda
estim final reduc ep estim
also introduc revenu ebitda ep
estim respect
valuat trade ev/ebitda multipl forecast compar
peer averag also trade price-to-earnings earn
compar peer averag believ discount peer warrant
due declin growth flagship brand stagnant brand
click full note
catalyst ahead elev data vistagen
also
vistagen file march report net loss
end period cash balanc sheet
provid runway data elev trial expect
repres next inflect point compani
elev trial continu enrol major depress disord
mdd inadequ respons antidepress ad data expect
addit trial plan combin soc follow success
levodopa induc dyskinesia
second compound mdd vistagen second compound
develop mdd nasal spray activ gaba
crh pathway compound demonstr rapid ad effect
plan first line mdd
forget social anxieti disord sad pivot trial
sad approach initi compound demonstr
posit data repres signific market opportun
addit posit data gener anxieti disord may warrant
explor indic
valuat remain attract data approach recal anoth
nmda target drug mdd axsom nr demonstr
posit data back januari trial patient vs
share rose significantli elev data next
also watch vistagen pipelin
phase elev phase elev trial evalu
mdd adjunct fda-approv antidepress patient inadequ
respons trial multi-cent random double-blind placebo-control
design use sequenti parallel comparison design spcd order
minim placebo respons gener cohort placebo non-respond
random patient trial approach increasingli common
studi target enrol patient trial evalu
oral dose day day patient studi also take
regular antidepress regimen primari endpoint efficaci measur
decreas montgomery-asberg depress rate scale version
scale two week secondari endpoint includ safeti toler
measur sae depress measur time improv
scale
phase plan social anxieti disord sad vistagen
nasal spray design rapid onset minut treatment anxieti
compound activ nasal chemosensori receptor trigger fear/anxieti
suppress neural circuit alreadi demonstr efficaci phase trial
assess subject unit distress sud scale laboratory-
base public speak social situat challeng well phase
crossov studi demonstr signific reduct averag peak sud vs
placebo within one week treatment compani current make prepar
phase pivot trial sad expect initi addit
demonstr efficaci patient gener anxieti disord gad
phase studi patient gad reduct hamilton anxieti rate
scale vs placebo electrophysiolog chang concord reduct
anxieti also significantli greater group compani intend
advanc phase
click full note
maxim analyst coverag univers
sector coverag
care well
industri util
